PANACEABIO· Health Care› Biotechnology

Panacea Biotec Ltd

Stage 4 · Declining · week 2

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition produ… More about the company

₹357.6
-1.54% today
₹2,190 Cr · Small cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dBiotechnology 22.2%-22.2 pts
Loading price chart…
vs 52W High
-41.2%
₹296.1 lo₹607.8 hi
41.2% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 2
1w13w26w
Week 2 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-11.1%
200 DMA: ₹402.5 · rising
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.37x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -3.0% vs MA50 -13.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-6.2%
3M
-32.2%
6M
+11.0%
YTD
+0.4%
1Y
-11.9%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
Sector has 77 Stage 2 leaders. See Health Care Stage 2 →
Industry
Biotechnology
↓ Peaking
Stage 2%
22.2%
20d Δ
-22.2pp
1M return
-4.7%
3M return
+5.2%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Biotechnology Stage 2 →
Stage Cycle Timeline2023-07-12 → 2026-10-07
S2 27w
S4 19w
S2 23w
S4 24w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 5w → S2 27w → S3 5w → S4 19w → S1 2w → S2 23w → S3 8w → S2 12w → S3 6w → S4 9w → S1 5w → S4 24w → S1 4w → S2 10w → S3 6w → S4 1w current
Total tracked: 168 weeks across 16 stage runs.
Scan Membership
Pullback Hunter
Latest: 2026-07-20
Prop Scan
Latest: 2026-07-20
Breakout Watch
Latest: 2026-06-09
40 appearances in last 60 days. First seen: 2024-08-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S4
Wk 2 · Vol 0.37x
2026-10-06S4
Wk 1 · Vol 0.53x
2026-10-05S4
Wk 1 · Vol 0.40x
2026-10-01S4
Wk 1 · Vol 0.46x
2026-09-30S4
Wk 1 · Vol 0.33x
2026-09-29S43→4
Wk 1 · Vol 0.41x
2026-09-28S3
Wk 6 · Vol 0.30x
2026-09-25S3
Wk 6 · Vol 0.44x
2026-09-24S3
Wk 6 · Vol 0.26x
2026-09-23S3
Wk 6 · Vol 0.20x
2026-09-22S3
Wk 5 · Vol 0.90x
2026-09-21S3
Wk 5 · Vol 0.30x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹392.4
200 DMA
₹402.5
52W High
₹607.8
52W Low
₹296.1
5D Low
₹350.3
Resistance levels (recent highs)
20d High
₹397.7
60d High
₹564
120d High
₹607.8
250d High
₹607.8
Next resistance
+11.2%
to 20d High
Ask the Market AI about PANACEABIOAsk →
Earnings Growth (YoY)
-12.2%
Revenue +1.0%
About this companyHealth Care· Biotechnology

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.